Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 208

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

Open access
Sang, Jim, Acquaviva, Jaime, Friedland, Julie C., Smith, Donald L., Sequeira, Manuel, Zhang, Chaohua, Jiang, Qin, Xue, Liquan, Lovly, Christine M., Jimenez, John-Paul, Shaw, Alice T., Doebele, Robert C., He, Suqin, Bates, Richard C., Camidge, D. Ross, Morris, Stephan W., El-Hariry, Iman, Proia, David A. · 2013 · Cancer Discovery

Abstract

EML4–ALK gene rearrangements define a unique subset of patients with non–small cell lung carcinoma (NSCLC), and the clinical success of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib in this population has become a paradigm for molecularly targeted therapy. Here, we show that the Hsp90 inhibitor ganetespib induced loss of EML4–ALK expression and depletion of multiple oncogenic signaling proteins in ALK-driven NSCLC cells, leading to greater in vitro potency, superior antitumor efficacy, and prolonged animal survival compared with results obtained with crizotinib. In addition, combinatorial benefit was seen when ganetespib was used with other targeted ALK agents both in vitro and in vivo. Importantly, ganetespib overcame multiple forms of crizotinib resistance, including secondary ALK mutations, consistent with activity seen in a patient with crizotinib-resistant NSCLC. Cancer cells driven by ALK amplification and oncogenic rearrangements of ROS1 and RET kinase genes were also sensitive to ganetespib exposure. Taken together, these results highlight the therapeutic potential of ganetespib for ALK-driven NSCLC. Significance: In addition to direct kinase inhibition, pharmacologic blockade of the molecular chaperone Hsp90 is emerging as a promising approach for treating tumors driven by oncogenic rearrangements of ALK. The bioactivity profile of ganetespib presented here underscores a new therapeutic opportunity to target ALK and overcome multiple mechanisms of resistance in patients with ALK-positive NSCLC. Cancer Discov; 3(4); 430–43. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 363

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-12-0440

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 208

Metadata

Authors
Sang, J., Acquaviva, J., Friedland, J. C., Smith, D. L., Sequeira, M., Zhang, C., Jiang, Q., Xue, L., Lovly, C. M., Jimenez, J.-P., Shaw, A. T., Doebele, R. C., He, S., Bates, R. C., Camidge, D. R., Morris, S. W., El-Hariry, I., & Proia, D. A.
Venue
Cancer Discovery
Published
2013-04-01
Volume
3
Issue
4
Pages
430-443
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W2136245016
Cited by
208
References
6
FWCI
32.40
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/2159-8290.cd-12-0440
The paper
Sang, J., Acquaviva, J., Friedland, J. C., Smith, D. L., Sequeira, M., Zhang, C., Jiang, Q., Xue, L., Lovly, C. M., Jimenez, J.-P., Shaw, A. T., Doebele, R. C., He, S., Bates, R. C., Camidge, D. R., Morris, S. W., El-Hariry, I., & Proia, D. A. (2013). Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung Cancer. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-12-0440

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.